| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1191/0961203304lu1018oa Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?Centre for Rheumatology, The Middlesex Hospital, University College London, UK
Centre for Rheumatology, The Middlesex Hospital, University College London, UK
Centre for Rheumatology, The Middlesex Hospital, University College London, UK, d.isenberg{at}ud.ac.uk B cell dysfunctionand pathogenicautoantibodyformationare thoughtto be criticalin the pathogenesis of systemic lupus erythematosus (SLE). In this review we will summarize the results of attempts to utilize B cell depletion, based on the use of a chimeric monoclonalantibody(MAb) specific for human CD20, rituximab, for the treatment of patients with SLE.
Key Words: anti-CD20 rituximab systemic lupus erythematosus
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||

